The Pink Pill's Paradox: Eckert's TIME Honor Caps a Contentious Quest

RALEIGH, NC – February 17, 2026 – Cindy Eckert, the founder and CEO of Sprout Pharmaceuticals, has been named to the 2026 TIME100 Health list, a recognition placing her among the world's most influential figures in healthcare. The honor comes just two months after a landmark regulatory victory for her company's flagship product, Addyi, often dubbed the "pink pill." But behind the accolade lies a complex and contentious history that has ignited a fierce debate about women's health, pharmaceutical marketing, and gender bias in medicine.

Eckert's inclusion on the prestigious list, which celebrates leaders reshaping global health, is tied directly to the U.S. Food and Drug Administration's decision in December 2025. The agency significantly expanded the approval for Addyi, a daily pill for Hypoactive Sexual Desire Disorder (HSDD), or clinically diagnosed low libido. Originally approved in 2015 only for premenopausal women, the drug can now be prescribed to all women under 65, regardless of their menopausal status. This move potentially opens the treatment to millions more women in the United States.

"Every disruptor dreams of the moment that culture reflects that what they've done has made a difference," Eckert said in a statement. "Impact is the ultimate award." The recognition from TIME, which also honored leaders from pharmaceutical giants like Merck and Eli Lilly, signals a growing mainstream acceptance of women's sexual health as a critical component of overall wellness.

A Landmark Decision for an Overlooked Condition

HSDD is recognized as the most common form of female sexual dysfunction, with the Mayo Clinic estimating it impacts as many as 40% of women. Characterized by a persistent and distressing lack of sexual desire, the condition has long been relegated to the margins of medicine, often dismissed as a psychological issue or an inevitable part of aging. Addyi, known chemically as flibanserin, is a non-hormonal medication that works on brain neurotransmitters—dopamine, norepinephrine, and serotonin—to influence sexual desire.

The expanded FDA approval was a watershed moment, validating a decade-and-a-half-long crusade by Eckert. She has steadfastly argued that women deserve the same science-backed treatment options long afforded to men for sexual dysfunction. The decision now makes Addyi an option for perimenopausal and postmenopausal women, a demographic that frequently reports changes in sexual desire.

A Contentious Path to Approval

Despite the recent triumphs, Addyi's journey has been anything but smooth. Its history is a case study in pharmaceutical perseverance and controversy. Originally developed as an antidepressant by Boehringer Ingelheim, flibanserin was repurposed after trial participants reported an increase in libido. However, the FDA rejected the drug twice, in 2010 and 2013, citing what it deemed modest efficacy and significant side effects, including dizziness, nausea, and fatigue.

In response, Eckert's Sprout Pharmaceuticals launched an aggressive public relations and lobbying effort called "Even the Score." The campaign accused the FDA of gender bias, pointing to the numerous approved drugs for male sexual dysfunction while women had none. The narrative proved powerful, framing the issue as one of fairness and equality. Critics, however, argued the campaign was a misleading, industry-funded effort to pressure regulators. They noted that drugs for erectile dysfunction like Viagra work by increasing blood flow, a physiological mechanism, whereas Addyi targets the far more complex chemistry of desire in the brain.

Ultimately, the FDA approved Addyi in August 2015 but with its strongest safety alert: a black box warning. The warning highlights the risk of severe hypotension (low blood pressure) and syncope (fainting), particularly when taken with alcohol. This has remained a central point of concern, with patients advised to take the pill at bedtime and carefully manage or avoid alcohol consumption.

Less than two days after securing this hard-won approval, Eckert sold Sprout to Valeant Pharmaceuticals for $1 billion. But under Valeant, sales languished, and in 2018, Eckert reacquired the company and its drug, vowing to make Addyi accessible and affordable.

Efficacy, Safety, and the Market Reality

Even with expanded approval, the debate over Addyi's place in medicine continues. Clinical trials have consistently shown its effects to be modest. On average, women taking Addyi reported approximately half to one additional satisfying sexual event per month compared to those taking a placebo. For some women and their doctors, this improvement is a meaningful change in quality of life, but for others, it raises questions about whether the benefits outweigh the risks.

The company's marketing practices have also remained under a microscope. Sprout has received multiple warning letters from the FDA's Office of Prescription Drug Promotion, including one as recently as June 2025. The agency cited the company for making "false or misleading claims" and omitting crucial risk information in promotional materials, calling the violations "especially problematic" given the drug's serious potential side effects.

In the marketplace, Addyi faces competition from Vyleesi (bremelanotide), an on-demand injectable for HSDD approved in 2019. Unlike the daily Addyi pill, Vyleesi is self-administered as needed before sexual activity. The expanded approval for Addyi, however, gives it a significant advantage by granting access to the large postmenopausal market, setting the stage for a new phase of competition in the slowly growing field of women's sexual health therapeutics.

From the Pharmacy to the Big Screen

The cultural conversation ignited by Eckert and her pink pill is now poised to reach an even wider audience. An award-winning independent documentary, The Pink Pill, is set to begin streaming on Paramount+ on March 6, just ahead of International Women's Day. The film chronicles Eckert's relentless campaign to bring Addyi to market and her battle against what she portrays as a systemic double standard in medicine. Having already earned an Audience Award at the prestigious DOC NYC film festival, the documentary frames the story not just as a business venture but as a fight for healthcare equality.

As Eckert accepts her place on the TIME100 Health list, her story serves as a powerful symbol of a shifting landscape. The journey of a single, controversial pill has forced a broader reckoning, pushing a once-taboo topic into the mainstream and challenging the medical establishment to take women's sexual health seriously. The ultimate impact, however, will be measured not just in awards or film premieres, but in the long-term health outcomes for the millions of women now navigating these new treatment options.